Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity
Read moreConsidered an advanced therapy medicine, it was designed by the Tissue Engineering Group of the Department of Histology of the Faculty of Medicine of the UGR and the Biosanitary Research Institute ibs...
Read moreEste nuevo fármaco recibe luz verde para el tratamiento de personas con síntomas tempranos del Alzheimer.
Read moreR&D investments of € 4.6 million were made, of which € 4.2 million in development and € 0.4 million in research. Following the completion of the PORTICO clinical trial, the R&D investment intens...
Read moreLa Agencia Europea del Medicamento ha cambiado de opinión y respalda la utilización de este medicamento para el tratamiento del alzhéimer en fases iniciales. Aunque reduce un 27 % el deterioro cogn...
Read moreNasucure es una pomada nasal hidratante y regeneradora, que está diseñada para aliviar la sequedad y la congestión nasal de manera rápida, efectiva y segura, brindando el bienestar que realmente m...
Read moreA study led by Dr. Ariadna Tibau, researcher at the Sant Pau Research Institute (IR Sant Pau) and oncologist at Hospital de Sant Pau, was recently published in the journal JAMA Network Open. The artic...
Read moreA new guide has been published by the Spanish Agency of Medicines and Medical Devices (AEMPS), providing a consolidated reference for regulatory requirements applicable to the marketing of medical dev...
Read moreApTOLL completó un estudio clínico de Fase 1b/2 para el ictus isquémico agudo con resultados positivos. Merck asumirá el desarrollo clínico y la comercialización del fármaco.
Read moreTime matters for patients in need, and new research shows integrated services can reduce Phase I-III study times by up to nearly three years, generating strong ROI for biotech and biopharma customers ...
Read moreMinoryx Therapeutics today announce that the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL®) has been submitted to the European Medicines Agency (EM...
Read moreFollowing the EMA's positive opinion in July, the European Commission has now authorized the drug for marketing.
Read more